GSA Capital Partners LLP Acquires 10,581 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

GSA Capital Partners LLP boosted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 191.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,114 shares of the biopharmaceutical company’s stock after purchasing an additional 10,581 shares during the quarter. GSA Capital Partners LLP’s holdings in Celldex Therapeutics were worth $548,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after buying an additional 2,664,915 shares during the period. Novo Holdings A S acquired a new position in shares of Celldex Therapeutics in the second quarter valued at approximately $31,458,000. Point72 Asset Management L.P. boosted its holdings in shares of Celldex Therapeutics by 51.0% in the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after buying an additional 654,194 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Celldex Therapeutics by 19.8% in the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after buying an additional 604,251 shares during the period. Finally, Marshall Wace LLP boosted its holdings in shares of Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after buying an additional 479,068 shares during the period.

Insider Transactions at Celldex Therapeutics

In other Celldex Therapeutics news, CEO Anthony S. Marucci purchased 11,500 shares of Celldex Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.80% of the company’s stock.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $24.98 on Wednesday. Celldex Therapeutics, Inc. has a 52-week low of $22.93 and a 52-week high of $53.18. The firm has a 50 day moving average price of $31.51 and a two-hundred day moving average price of $35.27. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -9.72 and a beta of 1.60.

Analyst Ratings Changes

CLDX has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target for the company. The Goldman Sachs Group started coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, November 7th. Finally, Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.